Evidence map›Paper›PMID 35578271›Full record

ArticleTrials2022

Reduced anticoagulation targets in extracorporeal life support (RATE): study protocol for a randomized controlled trial.

Olivier van Minnen, Annemieke Oude Lansink-Hartgring, Bas van den Boogaard, Judith van den Brule, Pierre Bulpa, Jeroen J H Bunge, Thijs S R Delnoij, Carlos V Elzo Kraemer, Marijn Kuijpers, Bernard Lambermont and 14 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04536272 (Reduced Anticoagulation Targets in ECLS), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04536272 phase3completednot on this map

Reduced Anticoagulation Targets in ECLS (RATE)

TypeinterventionalSponsorUniversity Medical Center GroningenRan2020 to 2025Enrolled330ConditionsHeart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation, BleedingArmsHeparin, LMWH
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. There Will be Blood-But Maybe Less with Prostaglandin EAmerican journal of respiratory and critical care medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 2 countries.

Olivier van MinnenDepartment of Critical Care, University Medical Center Groningen, Room R3.904, PO BOX 30001, 9700, RB, Groningen, The Netherlands. o.van.minnen@umcg.nl.ORCID http://orcid.org/0000-0002-4315-4072
Annemieke Oude Lansink-HartgringDepartment of Critical Care, University Medical Center Groningen, Room R3.904, PO BOX 30001, 9700, RB, Groningen, The Netherlands.
Bas van den BoogaardDepartment of Intensive Care, OLVG, Amsterdam, The Netherlands.
Judith van den BruleDepartment of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Pierre BulpaDepartment of Intensive Care, CHU UCL Namur site Mont-Godinne, Yvoir, Belgium.
Jeroen J H BungeDepartment of Intensive Care Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Thijs S R DelnoijDepartment of Intensive Care Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Carlos V Elzo KraemerDepartment of Intensive Care Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Marijn KuijpersDepartment of Intensive Care Medicine, Isala Clinics, Zwolle, The Netherlands.
Bernard LambermontDepartment of Intensive Care, CHU Sart Tilman, Liege, Belgium.
Jacinta J MaasDepartment of Intensive Care Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Jesse de MetzDepartment of Intensive Care, OLVG, Amsterdam, The Netherlands.
Isabelle MichauxDepartment of Intensive Care, CHU UCL Namur site Mont-Godinne, Yvoir, Belgium.
Ineke van de PolDepartment of Intensive Care Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands.
Marcel van de PollDepartment of Intensive Care Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
S Jorinde RaasveldDepartment of Intensive Care Medicine, Amsterdam University Medical Center, Location AMC, Amsterdam, The Netherlands.
Matthias RaesDepartment of Intensive Care, University Hospital Brussels, Brussels, Belgium.
Dinis Dos Reis MirandaDepartment of Intensive Care Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Erik ScholtenDepartment of Intensive Care Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands.
Olivier SimonetDepartment of Intensive Care, Centre Hospitalier de Wallonie Picarde (CHwapi), Tournai, Belgium.
Fabio S TacconeDepartment of Intensive Care, Hôpital Erasme Bruxelles, Brussels, Belgium.
Frederic VallotDepartment of Intensive Care, Centre Hospitalier de Wallonie Picarde (CHwapi), Tournai, Belgium.
Alexander P J VlaarDepartment of Intensive Care Medicine, Amsterdam University Medical Center, Location AMC, Amsterdam, The Netherlands.
Walter M van den BerghDepartment of Critical Care, University Medical Center Groningen, Room R3.904, PO BOX 30001, 9700, RB, Groningen, The Netherlands.
University Medical Center Groningen · NLAmsterdam University Medical Centers · NLCentre Hospitalier de Wallonie Picarde · BECHU Dinant Godinne UCL Namur · BEErasmus MC · NLLeiden University Medical Center · NLMaastricht University · NLOLVG · NLSt. Antonius Ziekenhuis · NLCentre Hospitalier Universitaire de Liège · BEErasmus Hospital · BEIsala · NLRadboud University Nijmegen · NL

Funding

ZonMw 848018014
6 · The paper itself

Abstract

backgroundAlthough life-saving in selected patients, ECMO treatment still has high mortality which for a large part is due to treatment-related complications. A feared complication is ischemic stroke for which heparin is routinely administered for which the dosage is usually guided by activated partial thromboplastin time (aPTT). However, there is no relation between aPTT and the rare occurrence of ischemic stroke (1.2%), but there is a relation with the much more frequent occurrence of bleeding complications (55%) and blood transfusion. Both are strongly related to outcome.

methodsWe will conduct a three-arm non-inferiority randomized controlled trial, in adult patients treated with ECMO. Participants will be randomized between heparin administration with a target of 2-2.5 times baseline aPTT, 1.5-2 times baseline aPTT, or low molecular weight heparin guided by weight and renal function. Apart from anticoagulation targets, treatment will be according to standard care. The primary outcome parameter is a combined endpoint consisting of major bleeding including hemorrhagic stroke, severe thromboembolic complications including ischemic stroke, and mortality at 6 months. DISCUSSION: We hypothesize that with lower anticoagulation targets or anticoagulation with LMWH during ECMO therapy, patients will have fewer hemorrhagic complications without an increase in thromboembolic complication or a negative effect on their outcome. If our hypothesis is confirmed, this study could lead to a change in anticoagulation protocols and a better outcome for patients treated with ECMO.

trial registrationClinicalTrials.gov NCT04536272 . Registered on 2 September 2020. Netherlands Trial Register NL7969.

Indexed as

Extracorporeal Membrane OxygenationIschemic StrokeAdultAnticoagulantsEquivalence Trials as TopicHeparinHeparin, Low-Molecular-WeightHumansRandomized Controlled Trials as TopicAnticoagulantsHeparinHeparin, Low-Molecular-WeightAnticoagulationComplicationsECMO

Identifiers

PMID35578271
PMCPMC9108348
OpenAlexW4280526332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.